KYTX stock forecast, quote, news & analysis
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company... Show more
Why Kyverna Therapeutics (KYTX) Stock Is Down -16.6% in the Last 30 Days
Key Takeaways
- Kyverna Therapeutics (KYTX) declined roughly 16.6% over the last 30 days, from a closing price of $6.80 on September 30, 2026 to $5.67 on October 30, 2026.
- The decline occurred despite a series of positive clinical data releases, reflecting pronounced "sell-the-news" pressure after miv-cel readouts.
- Over the trailing quarter, shares are down approximately 22%, extending a multi-month slide from an early-July peak near $9.91.
- Key influences included one-year stiff person syndrome (SPS) and generalized myasthenia gravis (gMG) durability data, updated progressive multiple sclerosis (PMS) results, and a securities-litigation ruling.
- As a pre-revenue biotech, KYTX remains sensitive to cash-burn, dilution, and binary regulatory/clinical outcomes.
- Kyverna is targeting completion of its rolling Biologics License Application (BLA) for miv-cel in SPS during the fourth quarter of 2026, a pivotal near-term milestone.
- For additional context on valuation and upcoming catalysts, explore Kyverna's Price Targets, Earnings, and Forecast pages.
- To track automated strategies across the broader market, explore Trending AI Robots.
Kyverna Therapeutics (KYTX) Company Overview and Market Position
Kyverna Therapeutics is a late-stage clinical biopharmaceutical company developing cell therapies for autoimmune diseases. Its lead candidate, miv-cel (mivocabtagene autoleucel, also known as KYV-101), is an autologous, fully human CD19-targeting CAR T-cell therapy designed to achieve deep B-cell depletion and an immune-system "reset" with a single dose. The company is advancing a neuroimmunology franchise with initial indications in stiff person syndrome and generalized myasthenia gravis, along with earlier-stage programs in progressive multiple sclerosis and other B-cell-driven autoimmune conditions. Investors follow the stock for its first-to-market potential in autoimmune CAR T therapy and its progression toward a potential first U.S. regulatory approval.
Kyverna Therapeutics (KYTX) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, KYTX fell from $6.80 per share on September 30, 2026 to $5.67 on October 30, 2026, a decline of approximately 16.6%. The move was not a straight line: the shares briefly spiked following clinical data releases before reversing lower, a pattern consistent with profit-taking after catalysts that had already been widely anticipated.
The longer three-month trend shows a similar downward bias. From a late-July closing level near $7.30, the stock has declined roughly 22%, and it remains well below an early-July peak around $9.91. In short, the stock's positive data catalysts have not been enough to offset persistent selling pressure across the quarter.
What Drove KYTX Stock Price in the Last 30 Days
Several developments shaped KYTX's recent price action. On September 24, 2026, the company reported 12-month durability data showing sustained benefit from miv-cel in SPS and gMG, including a 49% median improvement in a timed walking test and 92% of SPS patients remaining free of chronic immunotherapies. Shares initially rose nearly 10% before reversing, as investors had largely priced in the readout. Full one-year registrational data were subsequently presented at the MS Toronto meeting in late October, and updated Phase 1 investigator-initiated data in progressive MS were released on October 23, 2026.
On the regulatory and legal front, Kyverna received a Regenerative Medicine Advanced Therapy (RMAT) designation for miv-cel in non-active secondary progressive MS, and on October 20, 2026 a federal court largely denied a motion to dismiss in a securities class action tied to the company's 2024 initial public offering. Analysts remained constructive, with Needham issuing a $25 price target on September 25, 2026. Despite these supportive items, the shares drifted lower, underscoring the heavy weight of pre-revenue execution risk, cash-burn concerns, and the dilution overhang that often accompanies a development-stage biotech.
What Drove KYTX Stock Performance Over the Last Quarter
The broader quarterly narrative is one of clinical progress meeting persistent selling. Kyverna initiated a rolling BLA submission for miv-cel in SPS and reached FDA alignment on its registrational trial design, while adding RMAT designations across SPS, gMG, and progressive MS. Financial results for the first quarter of 2026 showed a net loss of $39.7 million (or $0.66 per share) and cash, cash equivalents, and marketable securities of $236.4 million as of March 31, 2026. Yet, because the company generates no product revenue and approval remains pending, investors have continued to weigh the cost and timeline of commercialization against the promise of the pipeline. The result has been a multi-month decline despite what the company has characterized as positive, durable clinical data.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots from a broader platform offering hundreds of automated strategies across thousands of tickers. Rather than listing every bot, the page surfaces those that are top-performing and most relevant at a given time. Each bot differs in trading style, holding period, and performance metrics, so investors can compare approaches that align with their own objectives and risk tolerance. For traders seeking a systematic, data-driven complement to manual analysis, the page provides a convenient entry point to explore how AI is being applied across the market.
KYTX Stock Forecast Drivers: What Investors Should Watch Next
The most important near-term catalyst is the completion of the rolling BLA submission for miv-cel in stiff person syndrome, which management has targeted for the fourth quarter of 2026, along with the FDA's subsequent review. Investors should also monitor enrollment progress in the Phase 3 portion of the gMG trial, additional progressive MS data, and any updates on manufacturing capacity and commercial launch preparation. On the financial side, upcoming quarterly results, cash runway, and any capital-raising activity will be closely watched given the company's pre-revenue status. Regulatory decisions, safety updates, and the progression of the outstanding securities litigation may also influence sentiment. These factors carry meaningful uncertainty, and outcomes cannot be predicted with confidence.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
KYTX's Indicator enters downward trend
The Aroon Indicator for KYTX entered a downward trend on November 06, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 156 similar instances where the Aroon Indicator formed such a pattern. In 146 of the 156 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KYTX as a result. In 45 of 52 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for KYTX turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 24 similar instances when the indicator turned negative. In 21 of the 24 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KYTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where KYTX's RSI Indicator exited the oversold zone, 17 of 19 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +11.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where KYTX advanced for three days, in 121 of 135 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
KYTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. KYTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.823) is normal, around the industry mean (3.498). P/E Ratio (-1.671) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KYTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology